Skip to content

IDEAYA Biosciences

US · IDYA #2357 by market cap Listed 2019
25.56 -0.61 -2.33%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Recent news

  • Rating change
    J.P. Morgan Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $62
    Market Newswire · 2026/8/11
  • Rating change
    William Blair Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $51
    Market Newswire · 2026/10/16
  • Rating change
    A Quick Look at Today's Ratings for IDEAYA Biosciences(IDYA.US), With a Forecast Between $48 to $60
    Market Newswire · 2026/10/27
  • Rating change
    RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $48
    Market Newswire · 2026/10/28
  • Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $39
    Market Newswire · 2026/11/10
  • Rating change
    Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $57
    Market Newswire · 2026/11/4
  • Rating change
    LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $58
    Market Newswire · 2026/9/28
  • Rating change
    Citizens JMP Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $42
    Market Newswire · 2026/8/7
  • Rating change
    Guggenheim Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Raises Target Price to $57
    Market Newswire · 2026/9/9
  • Wedbush Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Raises Target Price to $63
    Market Newswire · 2026/11/4
  • Rating change
    Stifel Initiates IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $48
    Market Newswire · 2026/10/14
  • Rating change
    Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $44
    Market Newswire · 2026/10/29
  • Rating change
    Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating
    Market Newswire · 2026/9/1
  • Rating change
    Mizuho Securities Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50
    Market Newswire · 2026/9/1
  • Rating change
    Citi Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $65
    Market Newswire · 2026/9/11
  • Rating change
    UBS Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $50
    Market Newswire · 2026/10/28
  • RBC Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $45
    Market Newswire · 2026/11/4
  • Rating change
    Wedbush Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $60
    Market Newswire · 2026/10/26
  • Guggenheim Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $52
    Market Newswire · 2026/11/4
  • Citi Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Raises Target Price to $66
    Market Newswire · 2026/11/5
  • Rating change
    LifeSci Capital Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Maintains Target Price $62
    Market Newswire · 2026/7/27
  • Rating change
    Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Announces Target Price $63
    Market Newswire · 2026/7/7
  • Rating change
    Wedbush Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Raises Target Price to $60
    Market Newswire · 2026/8/6
  • Rating change
    Truist Financial Maintains IDEAYA Biosciences(IDYA.US) With Buy Rating, Cuts Target Price to $59
    Market Newswire · 2026/8/5
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Cadrenal Therapeutics, Inc. (CVKD) and IDEAYA Biosciences (IDYA)
    TipRanks · 2026/6/16

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

IDEAYA Biosciences discussion 0 comments

Add a comment